生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

已收盘 06-22 16:00:00

4,403.033

-91.653

-2.04%

最高4,494.492	最低4,284.793	成交量1.94亿
今开4,492.950	昨收4,494.687	日振幅4.67%
总市值0.00	流通市值0.00	总股本0.00
成交额54.40亿	换手率--	流通股本0.00
市净率5.015516	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":4403.033,"timestamp":1782115692879,"preClose":4494.6865,"halted":0,"volume":194212822,"delay":0,"changeRate":-0.020391,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-91.65332,"latestTime":"06-22 16:00:00","open":4492.95,"high":4494.4917,"low":4284.7925,"amount":5440262405,"amplitude":0.046655,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782178200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1782091800000,1782100800000],[1782104400000,1782115200000]],"pbRate":5.015516,"peRate":-302.6667,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161/tweets","defaultTab":"tweets","newsList":[{"id":"2645024752","title":"九源基因(02566)6月22日耗资约7.41万港元回购1.24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024752","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645024752?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:10","pubTimestamp":1782130212,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)公布，2026年6月22日耗资约7.41万港元回购1.24万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645408024","title":"再鼎医药(09688)授出受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645408024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645408024?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:05","pubTimestamp":1782129907,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于2026年6月17日(美国东部时间)根据2024年股权激励计划获授人授出部分受限制股份。所授出受限制股份数目(以美国存托股份计)：178,968。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","LU2488822045.USD","BK1574","BK4588","BK4548","BK1161","ZLAB","BK4531","BK4139","BK4526","BK4585","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024369","title":"翰思艾泰-B(03378)6月22日斥资59.7万港元回购2.24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024369","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645024369?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:55","pubTimestamp":1782129302,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B(03378)发布公告，于2026年6月22日斥资59.7万港元回购2.24万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1535","BK1173","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021276","title":"基石药业-B(02616)6月22日斥资235.13万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021276","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645021276?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:40","pubTimestamp":1782128421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，于2026年6月22日，该公司斥资235.13万港元回购50万股股份，每股回购价4.67-4.74港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457092.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161041485","title":"科济药业宣布全球首个实体瘤CAR-T疗法产品Satri-Cel获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1161041485","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161041485?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:21","pubTimestamp":1782127273,"startTime":"0","endTime":"0","summary":"科济药业-B（CARSGEN-B）宣布，其CAR-T细胞疗法产品Satri-Cel已获得批准，成为全球首个用于治疗实体瘤的CAR-T细胞疗法产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","02171","BK1574","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029851","title":"荃信生物-B(02509)6月22日斥资17.5万港元回购1.26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029851","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645029851?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:51","pubTimestamp":1782125469,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2026年6月22日斥资17.5万港元回购1.26万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645946025","title":"维升药业-B(02561)6月22日斥资9.5万港元回购4800股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645946025","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645946025?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:06","pubTimestamp":1782122785,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月22日斥资9.5万港元回购4800股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645002593","title":"歌礼制药-B(01672)6月22日斥资190.1万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645002593","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645002593?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:05","pubTimestamp":1782122704,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年6月22日，该公司斥资190.1万港元回购20万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1161","01672","BK1191","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645902563","title":"加科思-B(01167)6月22日耗资约49.89万港元回购11.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645902563","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645902563?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:00","pubTimestamp":1782122452,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)公布，2026年6月22日耗资约49.89万港元回购11.16万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023776","title":"和誉-B(02256)6月22日斥资53.58万港元回购6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023776","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645023776?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:53","pubTimestamp":1782122020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2026年6月22日斥资53.58万港元回购6万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK1161","IE00B543WZ88.USD","LU2488822045.USD","LU2778985437.USD","LU2476274308.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645028144","title":"昊海生物科技(06826)6月22日注销114.87万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645028144","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645028144?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:19","pubTimestamp":1782119954,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2026年6月22日，该公司注销114.87万股已回购股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645400610","title":"科济药业：自研CAR-T细胞治疗产品恺力美获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645400610","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645400610?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:53","pubTimestamp":1782118380,"startTime":"0","endTime":"0","summary":"6月22日，科济药业（02171）发布公告，国家药品监督管理局批准公司自主研发的Claudin18.2自体人源化CAR-T细胞治疗产品恺力美?（舒瑞基奥仑赛注射液）的新药上市申请。公告指出，恺力美?用于治疗Claudin18.2阳性、人表皮生长因子受体2（HER2）阴性，至少二线治疗失败的晚期胃/食管胃结合部腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223778072646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1585","IPOS","02171","CAR","BK1574","BK4022","BK4230","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645040412","title":"亿胜生物科技(01061)6月22日斥资18.64万港元回购7.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645040412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645040412?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:52","pubTimestamp":1782118339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿胜生物科技(01061)发布公告，于2026年6月22日该公司斥资18.64万港元回购7.1万股，回购价格为每股2.62-2.64港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01061","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166977495","title":"科济药业靶向GPC3 CAR-T疗法获NMPA批准用于晚期胃癌/胃食管结合部癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1166977495","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166977495?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:35","pubTimestamp":1782117334,"startTime":"0","endTime":"0","summary":"中国国家药品监督管理局已批准科济药业旗下的靶向GPC3的自体CAR-T细胞产品Satricabtagene Autoleucel，用于治疗既往接受过至少两种系统治疗的GPC3阳性晚期胃癌/胃食管结合部腺癌患者。此项批准标志着全球范围内首个针对GPC3靶点的CAR-T细胞疗法成功获批上市，为晚期胃癌患者带来了全新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","02171","BK1585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042702","title":"奥克股份：公司聚乙二醇产品主要应用于医药原料药、锂电新能源等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042702","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645042702?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:00","pubTimestamp":1782115246,"startTime":"0","endTime":"0","summary":"证券之星消息，奥克股份(300082)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：有人造肉研发团队使用聚乙二醇基材料作为支架进行肉细胞培育，公司聚乙二醇产品为什么不把此类用途列于官网？奥克股份回复：尊敬的投资者，您好！公司聚乙二醇产品主要应用于医药原料药、锂电新能源等领域。公司积极关注新领域的其他应用。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200020359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000941.SH","300082","BK1515","BK0028","09939","BK0070","BK0229","159875","399941","BK0201","BK1574","BK0155","BK1161","160640","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645414460","title":"“百万元一针”抗癌药有望降至万元，科济药业研发通用型CAR-T疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2645414460","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645414460?lang=zh_cn&edition=full","pubTime":"2026-06-22 14:57","pubTimestamp":1782111437,"startTime":"0","endTime":"0","summary":"科济药业创始人、首席执行官李宗海博士介绍，科济药业已将研发重心从自体CAR-T（嵌合抗原受体T细胞）转向通用型CAR-T疗法。自体CAR-T疗法利用人体自身免疫系统开展个体化治疗：先通过白细胞分离，从患者体内提取T细胞；再用CAR（嵌合抗原受体）对其修饰，让T细胞能识别癌细胞上特定抗原；完成基因工程修饰后，将CAR-T制剂回输给这名患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223777971181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02171","BK4022","BK1585","BK1161","BK1587","BK1574","CAR","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645823045","title":"翰思艾泰-B(03378)获纳入富时全球股票微盘股指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2645823045","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645823045?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:46","pubTimestamp":1782103587,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，根据富时罗素关于富时全球股票指数系列的季度检讨结果，翰思艾泰已被纳入富时全球股票微盘股指数。富时全球股票指数系列提供稳健的全球股票指数框架，该系列横跨全球49个发达和新兴市场，涵盖19,000多只大、中、小盘和微盘股票，是全球广泛认可的基准指数之一。董事会认为，此次公司获纳入富时全球股票微盘股指数，反映了国际资本市场对公司稳健基本面、创新能力及增长潜力的广泛认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰思艾泰-B(03378)获纳入富时全球股票微盘股指数","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1173","BK1535","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645430770","title":"银诺医药-B(02591)：收到国家药监局批准可开展依苏帕格鲁肽α用于治疗青少年肥胖症的Ib期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2645430770","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645430770?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:44","pubTimestamp":1782103443,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，于2026年6月17日，集团已收到中国国家药品监督管理局的批准，可开展集团依苏帕格鲁肽α用于治疗青少年肥胖症的Ib期临床试验。公司预期该临床试验将于2026年7月开始，并计划就该临床试验招募约36位参与者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"银诺医药-B(02591)：收到国家药监局批准可开展依苏帕格鲁肽α用于治疗青少年肥胖症的Ib期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147848245","title":"翰思艾泰-B将于2026年6月19日起纳入富时全球微型股指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1147848245","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147848245?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:19","pubTimestamp":1782101955,"startTime":"0","endTime":"0","summary":"翰思艾泰-B（Wuhan）股份有限公司宣布，公司股票将于2026年6月19日起正式被纳入富时全球微型股指数（FTSE Global Micro Cap Index）。\n此次入选标志着公司在资本市场的表现与规模获得了国际主流指数的认可。纳入该指数有望提升公司在全球投资者中的知名度，并可能吸引更多追踪该指数的被动资金流入。\n富时全球微型股指数由富时罗素（FTSE Russell）编制，旨在涵盖全球范围内符合特定市值标准的小型上市公司，为投资者提供重要的投资参考基准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","BK1161","BK1535","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110840346","title":"银诺医药-B获中国批准启动Efsubaglutide Alfa针对青少年肥胖症的Ib期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1110840346","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110840346?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:09","pubTimestamp":1782101359,"startTime":"0","endTime":"0","summary":"6月17日，广州银诺医药集团有限公司宣布，其研发的Efsubaglutide Alfa已获得中国监管部门的批准，将启动针对青少年肥胖症的Ib期临床试验。\n这一进展标志着该药物在拓展适应症方面取得了重要突破。Efsubaglutide Alfa是一种新型的胰高血糖素样肽-1（GLP-1）受体激动剂，此前已在成人肥胖症领域展现出潜力。此次获批进入青少年群体研究，有望为这一日益严峻的公共卫生问题提供新的治疗选择。\n临床试验的启动将遵循严格的研究方案，以评估药物在该特定年龄组中的安全性、耐受性及初步疗效。公司表示，将积极推进后续研究工作，并期待为全球肥胖症治疗领域贡献更多数据与方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0535},{"period":"6month","weight":-0.0687},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}